CU20200086A7 - Entidades peptídicas con actividad antimicrobiana frente a patógenos multi-drogoresistentes - Google Patents

Entidades peptídicas con actividad antimicrobiana frente a patógenos multi-drogoresistentes

Info

Publication number
CU20200086A7
CU20200086A7 CU2020000086A CU20200086A CU20200086A7 CU 20200086 A7 CU20200086 A7 CU 20200086A7 CU 2020000086 A CU2020000086 A CU 2020000086A CU 20200086 A CU20200086 A CU 20200086A CU 20200086 A7 CU20200086 A7 CU 20200086A7
Authority
CU
Cuba
Prior art keywords
drug
activity against
antimicrobial activity
resistant pathogens
against multi
Prior art date
Application number
CU2020000086A
Other languages
English (en)
Other versions
CU24750B1 (es
Inventor
Perez Hilda Elisa Garay
Vivian Montero-Alejo
Rolando Perdomo-Morales
González Amanda Vázquez
Original Assignee
Centro De Investig Y Desarrollo De Medicamentos Cidem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro De Investig Y Desarrollo De Medicamentos Cidem filed Critical Centro De Investig Y Desarrollo De Medicamentos Cidem
Priority to CU2020000086A priority Critical patent/CU24750B1/es
Priority to CA3199519A priority patent/CA3199519A1/en
Priority to PCT/CU2021/050011 priority patent/WO2022105948A2/es
Priority to US18/037,534 priority patent/US20240239849A1/en
Priority to MX2023005925A priority patent/MX2023005925A/es
Priority to JP2023523524A priority patent/JP7895939B2/ja
Priority to CN202180071094.XA priority patent/CN116406282A/zh
Priority to EP21865361.6A priority patent/EP4249500A2/en
Publication of CU20200086A7 publication Critical patent/CU20200086A7/es
Priority to CONC2023/0007878A priority patent/CO2023007878A2/es
Publication of CU24750B1 publication Critical patent/CU24750B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43509—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from crustaceans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Insects & Arthropods (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

<p>La presente invención describe compuestos peptídicos sintéticos que combaten microorganismos patógenos de naturaleza bacteriana, y que presentan como microorganismos multirresistentes a antibióticos convencionales. Además, describe terapias de combinación que contienen dichos péptidos. Se describen composiciones farmacéuticas que comprenden a los compuestos peptídicos y sus combinaciones.</p>
CU2020000086A 2020-11-19 2020-11-19 Entidades peptídicas con actividad antimicrobiana frente a patógenos multi-drogoresistentes CU24750B1 (es)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CU2020000086A CU24750B1 (es) 2020-11-19 2020-11-19 Entidades peptídicas con actividad antimicrobiana frente a patógenos multi-drogoresistentes
CA3199519A CA3199519A1 (en) 2020-11-19 2021-11-18 Peptide entities with antimicrobial activity against multi-drug resistant pathogens
PCT/CU2021/050011 WO2022105948A2 (es) 2020-11-19 2021-11-18 Entidades peptídicas con actividad antimicrobiana frente a patógenos multi-drogoresistentes
US18/037,534 US20240239849A1 (en) 2020-11-19 2021-11-18 Peptide entities with antimicrobial activity against multi-drug resistant pathogens
MX2023005925A MX2023005925A (es) 2020-11-19 2021-11-18 Entidades peptidicas con actividad antimicrobiana frente a patogenos multi-drogoresistentes.
JP2023523524A JP7895939B2 (ja) 2020-11-19 2021-11-18 多剤耐性病原体に対する抗菌活性を有するペプチド実体
CN202180071094.XA CN116406282A (zh) 2020-11-19 2021-11-18 具有针对多药耐药性病原体的抗微生物活性的肽实体
EP21865361.6A EP4249500A2 (en) 2020-11-19 2021-11-18 Peptide entities with antimicrobial activity against multi-drug resistant pathogens
CONC2023/0007878A CO2023007878A2 (es) 2020-11-19 2023-06-15 Entidades peptídicas con actividad antimicrobiana frente a patógenos multi-drogoresistentes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2020000086A CU24750B1 (es) 2020-11-19 2020-11-19 Entidades peptídicas con actividad antimicrobiana frente a patógenos multi-drogoresistentes

Publications (2)

Publication Number Publication Date
CU20200086A7 true CU20200086A7 (es) 2022-06-06
CU24750B1 CU24750B1 (es) 2025-06-11

Family

ID=80684162

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2020000086A CU24750B1 (es) 2020-11-19 2020-11-19 Entidades peptídicas con actividad antimicrobiana frente a patógenos multi-drogoresistentes

Country Status (9)

Country Link
US (1) US20240239849A1 (es)
EP (1) EP4249500A2 (es)
JP (1) JP7895939B2 (es)
CN (1) CN116406282A (es)
CA (1) CA3199519A1 (es)
CO (1) CO2023007878A2 (es)
CU (1) CU24750B1 (es)
MX (1) MX2023005925A (es)
WO (1) WO2022105948A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117756904B (zh) * 2023-12-22 2024-05-24 潍坊医学院 一种订书肽及其应用
CN118684742B (zh) * 2024-03-06 2026-04-07 广东医保药业有限公司 多肽及其与头孢噻肟舒巴坦的组合
CN121537497B (zh) * 2026-01-16 2026-05-29 南方海洋科学与工程广东省实验室(广州) 一种抗菌肽Mh-GC21及其前体和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69637731D1 (de) * 1995-08-23 2008-12-11 Univ British Columbia Antimikrobielle kationische peptide und methoden zu ihrer identifizierung
CU24073B1 (es) 2011-12-27 2015-01-29 Ct De Investigación Y Desarrollo De Medicamentos Cidem COMPOSICIÓN A PARTIR DE EXTRACTO DE HEMOCITOS DE LANGOSTA PARA LA DETECCIÓN DE LIPOPOLISACÁRIDOS, PEPTIDOGLICANOS Y 1,3-ß-D-GLUCANOS
EP3621632B1 (en) 2017-05-11 2025-08-13 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Antimicrobial peptides with alpha-core helices
JP2020527164A (ja) * 2017-06-13 2020-09-03 ライクスユニバーシタイト フローニンゲン グラム陰性病原体に対する抗微生物活性を示す抗微生物ペプチド及びその混合物
MX2020010071A (es) * 2018-03-29 2021-01-08 Contrafect Corp Polipeptidos anti-microbianos, derivados de bacteriofago, y sus usos contra bacterias gram negativas.
MX2021012166A (es) 2019-04-05 2021-11-03 Contrafect Corp Lisinas y sus derivados con actividad bactericida contra pseudomona aeruginosa, en la presencia de suero humano.

Also Published As

Publication number Publication date
WO2022105948A3 (es) 2022-10-20
JP2024508205A (ja) 2024-02-26
CO2023007878A2 (es) 2023-07-21
CN116406282A (zh) 2023-07-07
US20240239849A1 (en) 2024-07-18
CU24750B1 (es) 2025-06-11
WO2022105948A2 (es) 2022-05-27
MX2023005925A (es) 2023-05-29
EP4249500A2 (en) 2023-09-27
CA3199519A1 (en) 2022-05-27
JP7895939B2 (ja) 2026-07-28

Similar Documents

Publication Publication Date Title
CO2023007878A2 (es) Entidades peptídicas con actividad antimicrobiana frente a patógenos multi-drogoresistentes
MX2023007852A (es) Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
BR112017028413A2 (pt) peptídeos antimicrobianos estabilizados
EA202192738A1 (ru) Трициклические соединения, обеспечивающие разрушение белка ikaros и белка aiolos
MX2021014443A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
MX2020003581A (es) Compuestos monobactamicos cromanos para el tratamiento de infecciones bacterianas.
BR112018005114A2 (pt) um novo polipeptídeo de endolisina
CO2018010459A2 (es) Composiciones que comprenden cepas bacterianas
CO2018011701A2 (es) Formulaciones de antibióticos glicopeptídicos estabilizados
AR119025A1 (es) Composición que comprende un bacillus formador de biopelícula
MX364942B (es) Peptidos antimicrobianos.
CL2019003078A1 (es) Nuevos derivados de pirazol bicíclicos.
CL2018003265A1 (es) Modulares del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos.
CL2017002482A1 (es) Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas
BR112015029367A8 (pt) combinação compreendendo oxazolidinonaquinolonas, seu uso, composição farmacêutica, e kit de partes
MX2017012073A (es) Compuestos de minociclina para biodefensas.
MX2021015961A (es) Moleculas novedosas.
BR112022000041A2 (pt) Inibidores de detecção de quorum e / ou metabólitos pósbióticos e métodos relacionados
CL2021003317A1 (es) Medicamento y uso del mismo para tratar infecciones bacterianas que involucran una biopelícula.
CL2017002451A1 (es) Compuestos heterocíclicos novedosos y su uso en la prevención o tratamiento de las infecciones bacterianas
CO2022009260A2 (es) Composiciones farmacéuticas oftálmicas
MX2021014310A (es) Formulaciones de terlipressina.
MX2021009443A (es) Composiciones que contienen bacterias productoras de bacillaeno o preparaciones de las mismas.
BR112021022902A2 (pt) Métodos e composições que compreendem variantes de proteína a staphylococcus (spa)
MX2019002248A (es) Proteina de union al factor h modificada.